A prospective cohort study to investigate the use of avb3-integrin scintigraphic imaging with 99mTc-NC100692 as a surrogate endpoint for therapeutic interventions in patients with myocardial infarction.

Maastricht University Medical Center0 个研究点目标入组 123 人开始时间: 待定最近更新: 2024年2月28日

试验速览

•1. The subject has had no previous MI (a previous MI/scar could potentially result in tracer uptake and therefore interfere with the imaging outcome), presents with acute MI and has undergone coronary angiography during which percutaneous coronary intervention (PCI) or no intervention may be performed. The documentation of coronary anatomy and disease will be linked to the imaging outcome;
•2. The subject is >18 years of age at study entry. Maximum age is 80 years, provided patients are in good condition;

•1. The subject was previously entered into this study or has participated in any other IMP study within 30 days of study entry, since this could interfere with the medications tested;
•2. The subject is scheduled to receive another IMP from time of entry into this study until completion of the follow-up period after the second injection proposed for this study, since this could interfere with the medications and endpoints tested;

发起方